Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Herpes Simplex Virus Treatment Market

Herpes Simplex Virus Treatment Market Trends

Report ID: GMI7466
Published Date: Nov 2023
Report Format: PDF

Download Free Sample

Herpes Simplex Virus Treatment Market Trends

The growing government funding and awareness play a pivotal role in driving the demand for market. For instance, in 2021, Federal Ministry of Education and Research (BMBF) provided funding of nearly USD 2.49 million to Friedrich-Alexander-Universität (FAU) for the development of a new drug against the herpes virus. Therefore, government funding is essential for maintaining and improving healthcare infrastructure, including clinics, laboratories, and healthcare services. A robust healthcare system ensures that individuals have access to appropriate testing, diagnosis, and treatment for HSV infections.
However, the unavailability of vaccines poses a significant restraint on the herpes simplex treatment market. The absence of a vaccine means there is no comprehensive management of herpes simplex infections, creating a gap in treatment sector. The unmet need for a reliable and accessible vaccine contributes to the ongoing challenges in controlling the spread of herpes simplex, impacting both individuals' health and the broader healthcare system.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Herpes simplex virus treatment industry was valued at USD 2.6 billion in 2022 and is projected to surpass USD 3.8 billion by 2032, driven by increasing prevalence of herpes infection, rising R&D, growing government funding, and increasing healthcare expenditure.

The HSV-1 segment held a market share of 83.2% in 2022 and is projected to witness substantial gains by 2032, driven by the increasing prevalence of HSV-1 infection among the population, along with the recurrent nature of oral herpes outbreaks.

North America herpes simplex virus treatment industry held a revenue share of 56.8% in 2022 & is anticipated to grow robustly through 2032 driven by significant burden of HSV infections and advanced healthcare infrastructure in the region.

GlaxoSmithKline plc, Pfizer Inc, Teva Pharmaceutical Industries Ltd, Glenmark Pharmaceuticals Limited, Amneal Pharmaceuticals LLCare some of the major industry contenders.